|Articles|November 1, 2022

Supplements and Featured Publications

  • Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
  • Volume 28
  • Issue 12

What are the current challenges to wider biosimilar use in the United States?

Plain Language Summary

Plain Language Summary

Click the image to open in a new window.

Related to this article

Daniel Kyung Min, PharmD | Image: LinkedIn
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.